Literature DB >> 12429618

Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women.

Asha Rathi1, Arvind K Virmani, John O Schorge, Keren J Elias, Riichiroh Maruyama, John D Minna, Samuel C Mok, Luc Girard, David A Fishman, Adi F Gazdar.   

Abstract

PURPOSE: The purpose of this research was to examine the DNA methylation profiles of primary sporadic ovarian cancers and ovarian tissues from high-risk women. EXPERIMENTAL
DESIGN: We analyzed the DNA methylation status of nine cancer-related genes in 49 primary ovarian tumors, 39 nonmalignant ovarian tissues obtained from 16 women with no known risk and from 23 high-risk women with a strong family history of breast and/or ovarian cancer or BRCA1 germ-line mutations, and 11 ovarian cancer cell lines, by methylation-specific PCR.
RESULTS: Our findings are as follows: (a) methylation rates of four of nine genes, RASSF1A (41%), HIC1 (35%), E-cadherin (29%), and APC (18%) were significantly higher in tumors compared with controls. At least one of the four genes was methylated in 76% of the tumors; (b) a low frequency of methylation was present in nonmalignant tissues; (c) no significant differences in methylation frequencies were seen between the nonmalignant ovarian tissues from women at high-risk and those with no known risk of developing ovarian cancer; (d) methylation of the BRCA1 gene was found in 10% of sporadic tumors but in none of the samples from women with a germ-line BRCA1 mutation; and (e) ovarian cancer cell lines showed a similar frequency of methylation to ovarian tumors except for the HIC1 gene.
CONCLUSIONS: Our results suggest that aberrant methylation of specific genes, including two not described previously, may be important in ovarian cancer pathogenesis but not in ovaries at risk for cancer development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429618

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  35 in total

1.  Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.

Authors:  Joseph Kwong; Ji-Young Lee; Kwong-Kwok Wong; Xiaofeng Zhou; David T W Wong; Kwok-Wai Lo; William R Welch; Ross S Berkowitz; Samuel C Mok
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

2.  Methylation profile in benign, borderline and malignant ovarian tumors.

Authors:  K F Tam; V W S Liu; S S Liu; P C K Tsang; A N Y Cheung; A M W Yip; H Y S Ngan
Journal:  J Cancer Res Clin Oncol       Date:  2006-12-20       Impact factor: 4.553

Review 3.  Translational application of epigenetic alterations: ovarian cancer as a model.

Authors:  Marie E Maradeo; Paul Cairns
Journal:  FEBS Lett       Date:  2011-03-12       Impact factor: 4.124

4.  Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development.

Authors:  Rahul Bhagat; Shilpa Chadaga; C S Premalata; G Ramesh; C Ramesh; V R Pallavi; Lakshmi Krishnamoorthy
Journal:  Cell Oncol (Dordr)       Date:  2012-10-10       Impact factor: 6.730

5.  Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer.

Authors:  Yu Yuecheng; Li Hongmei; Xin Xiaoyan
Journal:  Clin Exp Metastasis       Date:  2006-07-07       Impact factor: 5.150

Review 6.  Epigenomics and ovarian carcinoma.

Authors:  Leonel Maldonado; Mohammad Obaidul Hoque
Journal:  Biomark Med       Date:  2010-08       Impact factor: 2.851

7.  Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors.

Authors:  M Ehrlich; C B Woods; M C Yu; L Dubeau; F Yang; M Campan; D J Weisenberger; Ti Long; B Youn; E S Fiala; P W Laird
Journal:  Oncogene       Date:  2006-04-27       Impact factor: 9.867

8.  High-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistance.

Authors:  Michael Boettcher; Frank Kischkel; Jörg D Hoheisel
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

9.  Altered expression of β-catenin, E-cadherin, and E-cadherin promoter methylation in epithelial ovarian carcinoma.

Authors:  Rahul Bhagat; C S Premalata; V Shilpa; V R Pallavi; G Ramesh; C R Vijay; Lakshmi Krishnamoorthy
Journal:  Tumour Biol       Date:  2013-04-19

10.  Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53.

Authors:  Bridget A Quinn; Tiffany Brake; Xiang Hua; Kimberly Baxter-Jones; Samuel Litwin; Lora Hedrick Ellenson; Denise C Connolly
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.